Eli Lilly’s $LLY business has changed fast.
In the first half of 2026, Mounjaro and Zepbound brought in a combined $27.7 billion in revenue. That was about 65% of Lilly’s total revenue for the period.
Mounjaro alone generated $18.6 billion. Zepbound added another $9.1 billion. Everything else in the company combined was about $15.1 billion.
Lilly is no longer just a broad pharma company with a strong obesity and diabetes franchise. For now, its revenue base is heavily tied to GLP-1 demand.
Source: Eli Lilly 10-Q